🔎 Trials Near Me

Pradžia › Neuroblastoma › New York

Neuroblastoma klinikiniai tyrimai New York

13 tyrimai dėl Neuroblastoma ieško dalyvių vietose New York.

Miestai New York

Oficialus tyrimo tekstas (anglų kalba)

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  • Albany Medical Center, Albany
  • Roswell Park Cancer Institute, Buffalo
  • NYU Langone Hospital - Long Island, Mineola
  • ir dar 7
Renkami dalyviai3 fazė
Iki 30 metų · Visoms lytims · Atnaujinta 2026-10-02 · NCT06172296

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

  • Memorial Sloan Kettering Cancer Center, New York
Renkami dalyviai2 fazėLaukiami sveiki savanoriai
Visi amžiai · Visoms lytims · Atnaujinta 2026-09-30 · NCT04936529

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Memorial Sloan Kettering Cancer Center ( Site 1010), New York
  • New York Medical College ( Site 1023), Valhalla
Renkami dalyviai1/2 fazė
6 Months – 25 Years · Visoms lytims · Atnaujinta 2026-09-17 · NCT06395103

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

  • Memorial Sloan Kettering Cancer Center, New York
Renkami dalyviai2 fazė
18 Months – 19 Years · Visoms lytims · Atnaujinta 2026-08-28 · NCT06528496

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

  • Albany Medical Center, Albany
  • Maimonides Medical Center, Brooklyn
  • Roswell Park Cancer Institute, Buffalo
  • ir dar 8
Renkami dalyviai3 fazė
365 Days – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03126916

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Renkami dalyviai1/2 fazė
12 Months – 30 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT04851119

SPEARHEAD-3 Pediatric Study

  • Memorial Sloan Kettering Kids, New York
Renkami dalyviai1/2 fazė
Amžius nuo 2 iki 21 · Visoms lytims · Atnaujinta 2026-08-11 · NCT05642455

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

  • Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack
  • Memorial Sloan Kettering Westchester (Consent only), Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
  • ir dar 1
Renkami dalyviai2 fazė
Visi amžiai · Visoms lytims · Atnaujinta 2026-07-28 · NCT06057948

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • Memorial Sloan Kettering Cancer Center, New York
Renkami dalyviai2 fazė
Amžius 1 ir vyresni · Visoms lytims · Atnaujinta 2026-05-29 · NCT00107289

Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies

  • New York Medical College, Valhalla
Renkami dalyviai1 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-04-15 · NCT04308330

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

  • Albert Einstein College of Medicine, Children's Hospital at Montefiore, The Bronx
  • New York Medical Center/ Maria Fareri Children's Hospital, Valhalla
Renkami dalyviai2 fazė
Amžius nuo 1 iki 50 · Visoms lytims · Atnaujinta 2026-03-13 · NCT01804634

Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

  • Memorial Sloan Kettering Cancer Center, New York
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2025-10-15 · NCT00588068

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

  • Children's Hospital at Montefiore, The Bronx
Renkami dalyviai2 fazė
18 Months – 40 Years · Visoms lytims · Atnaujinta 2025-08-12 · NCT05135975

Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.